This version of the Guidance has been updated to reflect several important developments, including the recent approval of sofosbuvir/velpatasvir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

• Initial Treatment of HCV Infection
• Retreatment of Persons in Whom Prior Therapy has Failed
• Unique Patient Populations: Patients with Decompensated Cirrhosis

Other updates reflecting recent data are provided in:

• Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation
• Unique Patient Populations: Patients with HIV/HCV Coinfection
• Unique Patient Populations: Patients with Renal Impairment
• HCV Testing and Linkage to Care

Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:

• Monitoring Patients Who Are Starting Hepatitis C Treatment, Are On Treatment, or Have Completed Therapy

Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:

• Unique Patient Populations: Patients with HIV/HCV Coinfection
• Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation

Updated references have been provided throughout the Guidance.

This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir, together with new information regarding the use of testing for HCV resistance associated variants.

Updated recommendations reflecting this approval are provided in these sections:

• Initial Treatment of HCV Infection
• Retreatment of Persons in Whom Prior Therapy has Failed
• Unique Patient Populations: Patients with Renal Impairment

Other updates reflecting recent data are provided in:

• Unique Patient Populations: Patients with Decompensated Cirrhosis
• Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation
• HCV Testing and Linkage to Care

Updated recommendations regarding the monitoring of cirrhotic patients are also provided in:

• Monitoring Patients who are Starting Hepatitis C Treatment, are on Treatment, or have Completed Therapy section.

Drug-drug interaction updates are also provided, particularly as they relate to antiretroviral agents and calcineurin inhibitors in:

• Unique Patient Populations: Patients with HIV/HCV Coinfection
• Unique Patient Populations: Patients who Develop Recurrent HCV Infection Post-Liver Transplantation

Updated references have been provided throughout the Guidance.

In the Initial, Retreatment, and Monitoring sections, recommendations regarding the use of paritaprevir/ritonavir/ombitasvir plus dasabuvir in those with advanced liver disease have been revised based on an FDA warning issued on October 22, 2015.

View Official Press Release: When and In Whom to Initiate HCV Therapy Now Available at www.HCVguidelines.org

The following new section of the HCV Guidance has been released, Overview of Cost, Reimbursement, and Cost-Effectiveness Considerations for Hepatitis C Treatment Regimens.

The Initial, Retreatment, Monitoring, and Unique Populations (HIV/HCV Coinfection, Decompensated Cirrhosis, Post-Liver Transplantation, and Renal Impairment) sections have been revised based on newly available therapies and data.

HCV Guidance is available as an “Accepted Article” in HEPATOLOGY: 
doi: 10.1002/hep.27950

The When and In Whom to Initiate Therapy, Initial Treatment, Retreatment, Acute HCV Infection, and Unique Populations (HIV/HCV Coinfection, Decompensated Cirrhosis, and Renal Impairment) sections have been updated to reflect newly available data presented at the European Association for the Study of the Liver (EASL) International Liver Congress 2015.

A free HCV Guidance App, a digital version of the HCV Guidance, for your mobile device is available for download. For more information, please click here.

We are pleased to announce a new member to the HCV Guidance Panel! Tracy Swan is the Hepatitis/HIV Project Director for Treatment Action Group, and joins the Panel as a Community Representative.